Reportstack has announced a new market research publication on Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech which provides comprehensive understanding and unprecedented access to the discovery, preclinical and clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter discovery, preclinical and clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 8,000 links to online copies of actual discovery, preclinical and clinical stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The provide an orientation of discovery, preclinical and clinical stage deal making and business activities, provides an introduction to the report, provides an overview of why companies partner discovery, preclinical and clinical stage compounds/products, provides an overview of discovery, preclinical and clinical stage deals strategy and deal structure including numerous case studies. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract, provides a detailed analysis of discovery, preclinical and clinical stage payment terms including average headline, upfront, milestone and royalty rates for discovery deals, provides a review of the leading discovery, preclinical and clinical stage deal by headline value, provides a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of discovery, preclinical and clinical stage deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
The report provides a comprehensive and detailed review of discovery, preclinical and clinical stage partnering deals signed and announced since 2009, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in discovery, preclinical and clinical stage partnering and deal making since 2009.
In addition, a comprehensive appendix is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery, preclinical and clinical stage products and compounds.
Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech provides the reader with the following key benefits:
In-depth understanding of discovery, preclinical and clinical stage deal trends since 2009
Access to headline, upfront, milestone and royalty data
Analysis of the structure of discovery, preclinical and clinical stage agreements with numerous real life case studies
Detailed access to actual discovery, preclinical and clinical stage deals entered into by the leading fifty big pharma and big biotech companies
Insight into the terms included in a discovery, preclinical and clinical stage agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements Terms and Agreements in Pharm and Biotech is intended to provide the reader with an in-depth understanding and access to discovery, preclinical and clinical stage deal trends and structure of deals entered into by leading companies worldwide.
Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech includes:
Trends in discovery, preclinical and clinical stage dealmaking in the biopharma industry since 2009
Analysis of discovery, preclinical and clinical stage deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life discovery, preclinical and clinical stage deals
Access to over 8,000 discovery, preclinical and clinical stage deals
The leading discovery, preclinical and clinical stage deals by value since 2009
Most active discovery, preclinical and clinical stage dealmakers since 2009
The leading discovery, preclinical and clinical stage partnering resources
In Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharm and Biotech, the available contracts are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal type
Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 8,000 links to online copies of actual discovery, preclinical and clinical stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The provide an orientation of discovery, preclinical and clinical stage deal making and business activities, provides an introduction to the report, provides an overview of why companies partner discovery, preclinical and clinical stage compounds/products, provides an overview of discovery, preclinical and clinical stage deals strategy and deal structure including numerous case studies. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract, provides a detailed analysis of discovery, preclinical and clinical stage payment terms including average headline, upfront, milestone and royalty rates for discovery deals, provides a review of the leading discovery, preclinical and clinical stage deal by headline value, provides a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of discovery, preclinical and clinical stage deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
The report provides a comprehensive and detailed review of discovery, preclinical and clinical stage partnering deals signed and announced since 2009, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in discovery, preclinical and clinical stage partnering and deal making since 2009.
In addition, a comprehensive appendix is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery, preclinical and clinical stage products and compounds.
Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech provides the reader with the following key benefits:
In-depth understanding of discovery, preclinical and clinical stage deal trends since 2009
Access to headline, upfront, milestone and royalty data
Analysis of the structure of discovery, preclinical and clinical stage agreements with numerous real life case studies
Detailed access to actual discovery, preclinical and clinical stage deals entered into by the leading fifty big pharma and big biotech companies
Insight into the terms included in a discovery, preclinical and clinical stage agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements Terms and Agreements in Pharm and Biotech is intended to provide the reader with an in-depth understanding and access to discovery, preclinical and clinical stage deal trends and structure of deals entered into by leading companies worldwide.
Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech includes:
Trends in discovery, preclinical and clinical stage dealmaking in the biopharma industry since 2009
Analysis of discovery, preclinical and clinical stage deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life discovery, preclinical and clinical stage deals
Access to over 8,000 discovery, preclinical and clinical stage deals
The leading discovery, preclinical and clinical stage deals by value since 2009
Most active discovery, preclinical and clinical stage dealmakers since 2009
The leading discovery, preclinical and clinical stage partnering resources
In Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharm and Biotech, the available contracts are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal type
Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
To view the table of contents and know more details please visit Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report.
No comments:
Post a Comment